Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer

Cancer

Volumn 121, Issue 9, 2015, Pages 1422-1430

  Terry, Stéphane ^a,b,c,d   Nicolaiew, Nathalie ^a,b   Basset, Victor ^a,b,e,f   Semprez, Fannie ^a,b   Soyeux, Pascale ^a,b   Maillé, Pascale ^f   Vacherot, Francis ^a,b   Ploussard, Guillaume ^e,f   Londoño Vallejo, Arturo ^c   De La Taille, Alexandre ^a,b,f   Allory, Yves ^a,b,f  

^a INSERM U955   (France)

^b Research Unit UMRS955University of Paris Est   (France)

^c CNRS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

biomarker; ERG; prognosis; prostate cancer; SPINK1; TFF3

Indexed keywords

ONCOPROTEIN; SERINE PEPTIDASE INHIBITOR KAZAL TYPE 1; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; CARRIER PROTEIN; ERG PROTEIN, HUMAN; PEPTIDE; SPINK1 PROTEIN, HUMAN; TFF3 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CELL MOTILITY; CLINICAL FEATURE; CONTROLLED STUDY; GENETIC HETEROGENEITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SEQUENCE HOMOLOGY; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATIC NEOPLASMS; RISK;

ADULT; AGED; CARRIER PROTEINS; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; RISK; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928273139     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29233     Document Type: Article

References (43)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E,. European cancer mortality predictions for the year 2012. Ann Oncol. 2012; 23: 1044-1052.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
3. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555-565.
4. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24: 3973-3978.
5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648.
6. Rubin MA, Maher CA, Chinnaiyan AM,. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011; 29: 3659-3668.
7. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12: 590-598.
8. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13: 228-237.
9. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011; 24: 1128-1138.
10. Stenman UH, Huhtala ML, Koistinen R, Seppala M,. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer. 1982; 30: 53-57.
11. Higashiyama M, Monden T, Ogawa M, et al. Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol. 1990; 93: 8-13.
12. Ohmachi Y, Murata A, Matsuura N, et al. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer. 1993; 55: 728-734.
13. Ozaki N, Ohmuraya M, Hirota M, et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res. 2009; 7: 1572-1581.
14. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008; 13: 519-528.
15. Grupp K, Diebel F, Sirma H, et al. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate. 2013; 73: 1690-1698.
16. Lippolis G, Edsjo A, Stenman UH, Bjartell A. A, high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. Prostate Cancer Prostatic Dis. 2013; 16: 145-150.
17. Leinonen KA, Saramaki OR, Furusato B, et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22: 2333-2344.
18. Flavin R, Pettersson A, Hendrickson WK, et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014; 20: 4904-4911.
19. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE,. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate. 2004; 61: 209-214.
20. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate. 2004; 61: 215-227.
21. Park K, Chiu YL, Rubin MA, Demichelis F, Mosquera JM,. V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. Hum Pathol. 2013; 44: 2282-2292.
22. Taupin D, Ooi K, Yeomans N, Giraud A,. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest. 1996; 75: 25-32.
23. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GW,. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 1997; 183: 30-38.
24. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T,. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008; 14: 3395-3400.
25. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012; 25: 471-479.
26. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007; 97: 1690-1695.
27. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer [serial online]. BMC Cancer. 2008; 8: 230.
28. Rickman DS, Chen YB, Banerjee S, et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia. 2010; 12: 1031-1040.
29. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10: 177-188.
30. Campos-Fernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 2009; 55: 600-606.
31. Paul A, Ploussard G, Nicolaiew N, et al. Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol. 2010; 57: 267-272.
32. Eisen MB, Spellman PT, Brown PO, Botstein D,. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95: 14863-14868.
33. Schaefer G, Mosquera JM, Ramoner R, et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013; 16: 132-138.
34. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26: 4596-4599.
35. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008; 27: 253-263.
36. Leinonen KA, Tolonen TT, Bracken H, et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res. 2010; 16: 2845-2851.
37. Smith SC, Tomlins SA,. Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing? Clin Cancer Res. 2014; 20: 4733-4736.
38. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41: 524-526.
39. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22: 1083-1093.
40. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012; 181: 401-412.
41. Bhalla R, Kunju LP, Tomlins SA, et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol. 2013; 26: 835-848.
42. Pflueger D, Terry S, Sboner A, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011; 21: 56-67.
43. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153: 666-677.